Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- HC Wainwright initiated coverage on NRx Pharmaceuticals Inc (NASDAQ:NRXP) with a Buying rating and a price target of $2.
- Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's (NASDAQ:GILD) remdesivir in addition to Zyesami.
- The analyst is bullish on:
- Significant potential for NRX-101 for bipolar depressed patients that can rapidly stabilize patients with suicidal ideation and behavior. "We believe NRx's focus on treatments for bipolar depression with SIB makes NRx a leader in drug development in this field," HC Wainwright notes.
- Zyesami's nascent value as a novel potential therapy for acute and chronic lung disorders.
- "We believe uncertainty in the Zyesami clinical program has been priced into NRx stock, representing a value proposition ahead of key clinical milestones that could potentially lead to NRX-101 approval in 2024", the analysts added.
- Price Action: NRXP shares are down 5.75% at $0.57 during the market session on the last check Friday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!